A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study To Assess The Effect Of PF-05175157 As A Single Oral Dose On Metabolic And Cardiopulmonary Parameters During Steady State And Graded Exercise In Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 04 May 2016
At a glance
- Drugs PF 5175157 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 01 Oct 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jul 2013 Planned End Date changed from 1 Aug 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 20 May 2013 Planned end date changed from 1 Jul 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.